The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: Results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study

European Journal of Heart Failure

Volumn 14, Issue 6, 2012, Pages 642-651

  Ghali, Jalal K ^a   Orlandi, Cesare ^b   Abraham, William T ^c  

^a DETROIT MEDICAL CENTER   (United States)

^b Cardiokine Biopharma Inc   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Body weight; Heart failure; Hyponatraemia; Lixivaptan; Placebo

Indexed keywords

CREATININE; LIXIVAPTAN; MAGNESIUM; PLACEBO; POTASSIUM; SODIUM;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR SYSTEM EXAMINATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FEMALE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERNATREMIA; HYPERVOLEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOME SURVEY 6 ITEM COGNITIVE FUNCTION SCALE; MULTICENTER STUDY; OUTPATIENT; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; TRAIL MAKING TEST PART B; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; OUTPATIENTS; PYRROLES; RECEPTORS, VASOPRESSIN; STATISTICS AS TOPIC; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84861554558     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs051     Document Type: Article

References (30)

1. Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail 2010;16:419-431.
2. Stevenson LW, Tillisch JH, Hamilton M, Luu M, Chelimsky-Fallick C, Moriguchi J, Kobashigawa J, Walden J. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990;66: 1348-1354.
3. Steimle AE, Stevenson LW, Chelimsky-Fallic C, Fonarow GC, Hamilton MA, Moriguchi JD, Kartashov A, Tillisch JH. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997;96:1165-1172.
4. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140: 840-847.
5. Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, Abraham WT, Manda V, Bourge RC. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail 2010;3:580-587.
6. Dunlay SM, Gheorghiade M, Reid KJ, Allen LA, Chan PS, Hauptman PJ, Zannad F, Maggioni AP, Swedberg K, Konstam MA, Spertus JA. Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST Trial. Eur J Heart Fail 2010;12:367-374.
7. Shrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585.
8. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
9. Bayliss J, Norell M, Canepaanson R, Sutton G, Poole Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
10. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-338.
11. Greenberg A. Diuretic complications. Am J Med 2000;319:10-24.
12. Weber KT. Furosemide in the long term management of heart failure: the good the bad and the uncertain. J Am Coll Cardiol 2004;44:1308-1310.
13. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301-1307.
14. Cooper HA, Dries DL, Davis CE, SHen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100:1311-15.
15. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase on mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431-1439.
16. Hasselblad V, Stough WG, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE Trial. Eur J Heart Fail 2007;9:1064-1069.
17. Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, Baughman KL, Stevenson LW, Givertz MM. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 2008;14: 388-393.
18. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-858.
19. Aronson D, Verbalis JG, Mueller M, Krum H; DILIPO Investigators. Short and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO Study. Eur J Heart Fail 2011;13:327-336.
20. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006;290:F273-F278.
21. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49:2151-2159.
22. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD, Ru X, Mazandarani H, Tanikella T, Shepherd C, Ochalski L, Bailey T, Lock TY, Ning X, Taylor JR, Spinelli W. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. In: Zingg HH, Bourque CW, Bichet DG, eds. Vasopressin and Oxytocin. Molecular, Cellular, and Clinical Advances. New York: Plenum Press; 1998. p439-443.
23. AbrahamW, Ghali J, Braman V, Nirula A, Wisniacki N, Orlandi C. Effects of single dose administration of lixivaptan, a selective V2 receptor antagonist, or furosemide in healthy volunteers [abstract 1065]. Eur J Heart Fail 2010;12:1.
24. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-1621.
25. Martin P-Y, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, Schrier RW. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999;10: 2165-2170.
26. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-2696.
27. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; on behalf of the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive HF (ACTIVE in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening HF: a randomized controlled trial. JAMA 2004;291:1963-1971.
28. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. The EVEREST Outcome Trial. JAMA 2007;297:1319-1331.
29. Ghali JK. The COHERE Registry: hype or hope? J Card Fail 2000;6:3:272-275.
30. Abraham WT, Aranda JM, Boehmer JP, Elkayam U, Gilbert EM, Gottlieb SS, Hasenfuss G, Kukin M, Lowes BD, O'Connell JB, Tavazzi L, Feldman AM, Ticho B, Orlandi C. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA Class III/IV cardiac patient evaluation (THE BALANCE) Study. Clin Transl Sci 2010;3:249-253.